Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by American Century Companies Inc.

American Century Companies Inc. raised its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 55.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,412 shares of the specialty pharmaceutical company’s stock after purchasing an additional 57,406 shares during the quarter. American Century Companies Inc. owned 0.27% of Jazz Pharmaceuticals worth $19,755,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Lingohr Asset Management GmbH acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $354,000. Teacher Retirement System of Texas lifted its stake in shares of Jazz Pharmaceuticals by 15.6% in the fourth quarter. Teacher Retirement System of Texas now owns 17,372 shares of the specialty pharmaceutical company’s stock valued at $2,139,000 after purchasing an additional 2,346 shares during the period. Chesapeake Capital Corp IL purchased a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $376,000. Vinva Investment Management Ltd grew its position in Jazz Pharmaceuticals by 82.7% during the fourth quarter. Vinva Investment Management Ltd now owns 2,897 shares of the specialty pharmaceutical company’s stock worth $357,000 after buying an additional 1,311 shares during the period. Finally, Xponance Inc. increased its holdings in Jazz Pharmaceuticals by 17.7% in the fourth quarter. Xponance Inc. now owns 7,946 shares of the specialty pharmaceutical company’s stock valued at $979,000 after buying an additional 1,195 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 2.8 %

Shares of JAZZ opened at $122.92 on Monday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The firm has a market capitalization of $7.47 billion, a P/E ratio of 17.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock’s fifty day simple moving average is $132.30 and its 200 day simple moving average is $122.66.

Insider Transactions at Jazz Pharmaceuticals

In other news, CMO Robert Iannone sold 2,403 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total value of $332,599.23. Following the transaction, the chief marketing officer now owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. This trade represents a 2.93 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,022,825 in the last three months. 4.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JAZZ has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, HC Wainwright upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.